Loading...
XNAS
EOCN
Market cap3mUSD
Oct 23, Last price  
3.03USD
1D
-1.48%
1Q
-26.16%
Jan 2017
-99.94%
IPO
-99.99%
Name

Galmed Pharmaceuticals Ltd

Chart & performance

D1W1MN
XNAS:EOCN chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
95.89%
Shs. 5Y
-17.60%
Rev. 5Y
63.12%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
0000467,0001,085,0002,038,0000000000
Net income
-10m
L+37.14%
-3,149,000-17,485,000-9,103,000-10,622,000-16,953,000-12,299,000-9,856,000-20,461,000-28,771,000-32,467,000-17,866,000-6,912,000-7,517,000-10,309,000
CFO
-6m
L+7.40%
-3,079,000-2,524,000-9,241,000-8,474,000-12,129,000-12,067,000-9,023,000-14,937,000-26,287,000-32,892,000-18,501,000-6,137,000-5,880,000-6,315,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Key people

Allen Baharaff
President, Chief Executive Officer, Director
Doron Cohen
Chief Financial Officer · since 2022
Guy Nehemya
Chief Operating Officer, Data Protection Officer · since 2021
Yohai Stenzler
Chief Accounting Officer · since 2022
Liat Hayardeny
Chief Scientific Officer · since 2016
David Sidransky
Lead Independent Director · since 2019
Carol Brosgart
Independent Director · since 2017
Marshall Heinberg
Independent Director · since 2018
Shmuel Nir
Independent Director · since 2007
Amir Poshinski
Independent Director · since 2020
URL
https://www.galmedpharma.com
IPO date
Mar 13, 2014
Employees
4
Domiciled in
IL
Incorporated in
IL
Headquarters & legal address
AMOT HAMISHPAT BUILDING
8 SHAUL HAMELECH BOULEVARD
TEL AVIV, TA 64733
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT